Lista de obras -

15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau

artículo científico publicado en 2016

A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia

scientific article published on 03 September 2018

Adherence to the mediterranean diet and lymphoma risk in the european prospective investigation into cancer and nutrition

artículo científico publicado en 2019

An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement

artículo científico publicado en 2019

Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo.

artículo científico publicado en 2015

Association between anthropometry and lifestyle factors and risk of B cell lymphoma: an exposome wide analysis

artículo científico publicado en 2020

B cell lymphomas express CX3CR1 a non-B cell lineage adhesion molecule

artículo científico publicado en 2007

Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.

artículo científico publicado en 2009

Biphenotypic bigenotypic lymphoma with simultaneous expression of PAX5/BSAP and B- and T-cell markers

artículo científico publicado en 2007

Body composition measurements and risk of hematological malignancies: A population-based cohort study during 20 years of follow-up

artículo científico publicado en 2018

Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity.

artículo científico publicado en 2018

CD40 expression identifies a prognostically favourable subgroup of diffuse large B-cell lymphoma

artículo científico publicado en 2007

CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

artículo científico publicado en 2010

Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study.

artículo científico publicado en 2015

Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study

artículo científico publicado en 2016

Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration

artículo científico publicado en 2016

Clonal hematopoiesis evolves from pre-treatment clones and stabilizes after end of chemotherapy in patients with MCL

artículo científico publicado en 2020

Comorbidities and sex differences in causes of death among mantle cell lymphoma patients - A nationwide population-based cohort study

artículo científico publicado en 2019

Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas

scientific article published on 11 March 2019

Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma

scientific article published on 09 November 2017

Deregulation of COMMD1 is associated with poor prognosis in diffuse large B-cell lymphoma

artículo científico publicado en 2014

Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3

scientific article published on 21 December 2020

Detection of HPV mRNA in Self-collected Vaginal Samples Among Urban Ethiopian Women

artículo científico publicado en 2020

Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis

artículo científico publicado en 2005

Expanded clinical and experimental use of SOX11 - using a monoclonal antibody

artículo científico publicado en 2012

Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs

scientific article published on 25 July 2019

Frequency and clinical implications of SOX11 expression in Burkitt lymphoma

artículo científico publicado en 2016

Gene expression profiling indicates that immunohistochemical expression of CD40 is a marker of an inflammatory reaction in the tumor stroma of diffuse large B-cell lymphoma ⬇️

artículo científico publicado el 16 de marzo de 2012

Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma

artículo científico publicado en 2008

Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus

artículo científico publicado en 2017

Healthy lifestyle and the risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition study

artículo científico publicado en 2020

High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial

artículo científico publicado en 2013

High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma

artículo científico publicado en 2004

High serum vascular endothelial growth factor level is an adverse prognostic factor for high‐risk diffuse large B‐cell lymphoma patients treated with dose‐dense chemoimmunotherapy ⬇️

artículo científico publicado el 14 de septiembre de 2012

Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide

artículo científico publicado en 2019

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

artículo científico

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial

artículo científico publicado en 2018

Identification of B-cell lymphoma subsets by plasma protein profiling using recombinant antibody microarrays

artículo científico publicado en 2014

Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells

artículo científico publicado en 2009

Identification of uniquely expressed transcription factors in highly purified B-cell lymphoma samples

scientific article published on 01 June 2010

Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk

artículo científico publicado en 2020

Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study

artículo científico publicado en 2003

Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma - a Swedish lymphoma register study

artículo científico publicado en 2018

Impact of comorbidity on survival in peripheral T-cell lymphomas: A Swedish Lymphoma Registry study.

artículo científico publicado en 2017

Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study

artículo científico publicado en 2015

Improvement in survival of diffuse large B-cell lymphoma in relation to age, gender, International Prognostic Index and extranodal presentation: a population based Swedish Lymphoma Registry study

artículo científico publicado en 2014

Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden

scientific article published on 07 January 2021

Inflammatory potential of diet and risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition

scientific article published on 22 March 2019

Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines ⬇️

artículo científico publicado el 13 de febrero de 2011

International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma

artículo científico publicado en 2017

Is Good Clinical Practice Becoming Poor Clinical Care?

artículo científico publicado en 2017

KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study

scientific article published on 19 September 2019

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of mutations in mantle cell lymphoma

artículo científico publicado en 2018

Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma.

artículo científico publicado en 2016

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

artículo científico publicado en 2008

Long-term remission in idiopathic Castleman's disease with tocilizumab followed by consolidation with high-dose melphalan--two case studies

scientific article published on 25 August 2015

Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma

artículo científico publicado en 2018

Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009-trends in cure proportions by clinical characteristics

artículo científico publicado en 2015

Low RBM3 protein expression correlates with clinical stage, prognostic classification and increased risk of treatment failure in testicular non-seminomatous germ cell cancer

artículo científico publicado en 2015

Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy.

artículo científico publicado en 2010

Male gender is an adverse risk factor only in young patients with diffuse large B-cell lymphoma - a Swedish population-based study

artículo científico publicado en 2015

Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study

scientific article published on 16 December 2019

Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry

artículo científico publicado en 2011

Midline carcinoma with t(15;19) and BRD4-NUT fusion oncogene in a 30-year-old female with response to docetaxel and radiotherapy

artículo científico publicado en 2006

Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.

artículo científico publicado en 2016

Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases

artículo científico publicado en 2019

More Sun Light Exposure May Be Associated with Improved Overall Survival in Diffuse Large B-Cell Lymphoma. A Population Based Swedish Lymphoma Registry Study

Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma

artículo científico publicado en 2003

National e-library for standardized chemotherapy regimens

artículo científico publicado en 2020

No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study.

artículo científico publicado en 2016

Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.

artículo científico publicado en 2012

Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

artículo científico publicado en 2014

Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma

artículo científico publicado en 2008

Optimizing Outcome Prediction in Diffuse Large B-Cell Lymphoma by Use of Machine Learning and Nationwide Lymphoma Registries: A Nordic Lymphoma Group Study

scientific article published on 01 December 2018

Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma

artículo científico publicado en 2020

Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study

artículo científico publicado en 2017

Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

scientific article published on 01 May 2020

Patterns of Central Nervous System Relapse in Peripheral T-Cell Lymphomas – Population-Based Data from the Swedish Lymphoma Registry

Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo.

artículo científico publicado en 2015

Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma

artículo científico publicado en 2010

Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study.

artículo científico publicado en 2011

Population-Based Study of Treatment Guided by Tumor Marker Decline in Patients With Metastatic Nonseminomatous Germ Cell Tumor: A Report From the Swedish-Norwegian Testicular Cancer Group ⬇️

artículo científico publicado el 11 de abril de 2011

Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.

artículo científico publicado en 2009

Prognostic Implications of Specific Comorbidities in Mantle Cell Lymphoma Patients, a Swedish Lymphoma Registry Study

Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP.

artículo científico publicado en 2009

Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients

artículo científico publicado en 2010

Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN.

artículo científico publicado en 2007

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

artículo científico publicado en 2017

Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study

artículo científico publicado en 2014

Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry

artículo científico publicado en 2014

Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study

scientific article published on 06 February 2019

Reproductive Factors, Exogenous Hormone Use, and Risk of B-Cell Non-Hodgkin Lymphoma in a Cohort of Women From the European Prospective Investigation Into Cancer and Nutrition

Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study

artículo científico publicado en 2015

SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study

artículo científico publicado en 2014

SOX11 expression correlates to promoter methylation and regulates tumor growth in hematopoietic malignancies

artículo científico publicado en 2010

Season of diagnosis is associated with overall survival in patients with diffuse large B-cell lymphoma but not with Hodgkin's lymphoma - A population-based Swedish Lymphoma Register study

artículo científico publicado en 2016

Sick leave and disability pension among Swedish testicular cancer survivors according to clinical stage and treatment

artículo científico publicado en 2015

Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: a critical assessment of the R-IPI, IPI, and NCCN-IPI.

artículo científico publicado en 2017

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

artículo científico publicado en 2017

Targeting of B-cell receptor signalling in B-cell malignancies.

artículo científico publicado en 2017

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).

artículo científico publicado en 2009

The Prognostic Impact of Comorbidity in Peripheral T-Cell Lymphomas: a Swedish Lymphoma Registry Study

The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study.

artículo científico publicado en 2017

The impact of age on survival of diffuse large B-cell lymphoma - a population-based study.

artículo científico publicado en 2014

Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma

artículo científico publicado en 2007

Treatment Outcome in T-Cell Lymphoblastic Lymphoma in Adults - a Population-Based Study From the Swedish Lymphoma Registry

Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations.

artículo científico publicado en 2017

Treatment outcome in T-cell lymphoblastic lymphoma in adults - a population-based study from the Swedish Lymphoma Registry

artículo científico publicado en 2014

Trends in the prevalence, incidence and survival of non-Hodgkin lymphoma subtypes during the 21st century - a Swedish lymphoma register study

artículo científico publicado en 2020

Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network.

artículo científico publicado en 2014

Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)

scientific article published on 01 June 2018

miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator

artículo científico publicado en 2015

p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma

artículo científico publicado en 2020

Lista de obras de

15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau

A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia

Adherence to the mediterranean diet and lymphoma risk in the european prospective investigation into cancer and nutrition

An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement

Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo.

Association between anthropometry and lifestyle factors and risk of B cell lymphoma: an exposome wide analysis

B cell lymphomas express CX3CR1 a non-B cell lineage adhesion molecule

Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.

Biphenotypic bigenotypic lymphoma with simultaneous expression of PAX5/BSAP and B- and T-cell markers

Body composition measurements and risk of hematological malignancies: A population-based cohort study during 20 years of follow-up

Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity.

CD40 expression identifies a prognostically favourable subgroup of diffuse large B-cell lymphoma

CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study.

Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study

Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration

Clonal hematopoiesis evolves from pre-treatment clones and stabilizes after end of chemotherapy in patients with MCL

Comorbidities and sex differences in causes of death among mantle cell lymphoma patients - A nationwide population-based cohort study

Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas

Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma

Deregulation of COMMD1 is associated with poor prognosis in diffuse large B-cell lymphoma

Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3

Detection of HPV mRNA in Self-collected Vaginal Samples Among Urban Ethiopian Women

Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis

Expanded clinical and experimental use of SOX11 - using a monoclonal antibody

Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs

Frequency and clinical implications of SOX11 expression in Burkitt lymphoma

Gene expression profiling indicates that immunohistochemical expression of CD40 is a marker of an inflammatory reaction in the tumor stroma of diffuse large B-cell lymphoma ⬇️

Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma

Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus

Healthy lifestyle and the risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition study

High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial

High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma

High serum vascular endothelial growth factor level is an adverse prognostic factor for high‐risk diffuse large B‐cell lymphoma patients treated with dose‐dense chemoimmunotherapy ⬇️

Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial

Identification of B-cell lymphoma subsets by plasma protein profiling using recombinant antibody microarrays

Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells

Identification of uniquely expressed transcription factors in highly purified B-cell lymphoma samples

Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk

Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study

Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma - a Swedish lymphoma register study

Impact of comorbidity on survival in peripheral T-cell lymphomas: A Swedish Lymphoma Registry study.

Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study

Improvement in survival of diffuse large B-cell lymphoma in relation to age, gender, International Prognostic Index and extranodal presentation: a population based Swedish Lymphoma Registry study

Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden

Inflammatory potential of diet and risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition

Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines ⬇️

International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma

Is Good Clinical Practice Becoming Poor Clinical Care?

KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of mutations in mantle cell lymphoma

Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma.

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Long-term remission in idiopathic Castleman's disease with tocilizumab followed by consolidation with high-dose melphalan--two case studies

Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma

Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009-trends in cure proportions by clinical characteristics

Low RBM3 protein expression correlates with clinical stage, prognostic classification and increased risk of treatment failure in testicular non-seminomatous germ cell cancer

Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy.

Male gender is an adverse risk factor only in young patients with diffuse large B-cell lymphoma - a Swedish population-based study

Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study

Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry

Midline carcinoma with t(15;19) and BRD4-NUT fusion oncogene in a 30-year-old female with response to docetaxel and radiotherapy

Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.

Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases

More Sun Light Exposure May Be Associated with Improved Overall Survival in Diffuse Large B-Cell Lymphoma. A Population Based Swedish Lymphoma Registry Study

Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma

National e-library for standardized chemotherapy regimens

No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study.

Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.

Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma

Optimizing Outcome Prediction in Diffuse Large B-Cell Lymphoma by Use of Machine Learning and Nationwide Lymphoma Registries: A Nordic Lymphoma Group Study

Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma

Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study

Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

Patterns of Central Nervous System Relapse in Peripheral T-Cell Lymphomas – Population-Based Data from the Swedish Lymphoma Registry

Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo.